What is Immutep?
Established in 2001 and headquartered in Sydney, New South Wales, Immutep operates at the intersection of advanced immunology and oncology. The company specializes in the development of LAG-3 related immunotherapeutic products, which are designed to harness the body's immune system to combat various forms of cancer. Through its proprietary technology platform, Immutep has cultivated a robust portfolio of clinical-stage assets, positioning itself as a critical innovator in the global biopharmaceutical market. The firm's commitment to rigorous scientific inquiry and strategic partnerships has enabled it to navigate the complex regulatory and clinical environments inherent in the biotech industry, ensuring that its novel treatments move steadily toward commercial viability.
How much funding has Immutep raised?
Immutep has raised a total of $140M across 3 funding rounds:
Share Placement
$7M
Other Financing Round
$80M
Other Financing Round
$53M
Share Placement (2019): $7M, investors not publicly disclosed
Other Financing Round (2023): $80M, investors not publicly disclosed
Other Financing Round (2024): $53M, investors not publicly disclosed
Key Investors in Immutep
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Immutep?
With the recent infusion of capital, Immutep is poised to enter a critical phase of operational scaling and clinical advancement. The strategic allocation of these funds will likely prioritize the progression of its lead candidates through late-stage clinical trials, a move essential for achieving regulatory milestones and eventual market entry. Furthermore, the company is expected to enhance its research infrastructure, allowing for the exploration of new therapeutic applications for its LAG-3 platform. As the biotech sector continues to prioritize precision medicine, Immutep's focus on targeted immunotherapy provides a distinct competitive advantage. Investors and industry stakeholders will be closely monitoring the firm's ability to translate this financial momentum into tangible clinical outcomes, which will be the primary driver of long-term shareholder value and therapeutic impact in the oncology space.
See full Immutep company page
